Related Experiment Video
Updated: Aug 15, 2026
Live Cell Imaging of the TGF- β/Smad3 Signaling Pathway In Vitro and In Vivo Using an Adenovirus Reporter System
Published on: July 30, 2018
[Functional study on TGF-beta/Smads signaling pathway in human ovarian cancer cells]
Yun-Yan Zhang1, Xue Li, Li-Hua Sui
1Laboratory of Medical Genetics, Harbin Medical University, Harbin 150086, China.
Abstract:
Resistance to the growth inhibitory effects of transforming growth factor-beta (TGF-beta) is a characteristic of many transformed cells. The purpose of this study was to determine the response of ovarian cancer cells to TGF-beta1 and to investigate the roles of components of the TGF-beta/Smads signaling pathway in carcinogenesis of ovarian cancer. Three ovarian cancer cell lines, HO-8910, HO-8910PM and SKOV3, were treated with TGF-beta1 and assayed for growth response by MTT assay. Furthermore, expression and subcellular localization of the components of TGF-beta/Smads signaling pathway in these cell lines in the absence or presence of TGF-beta1 were determined by RT-PCR and immunofluorescence analysis. We found that proliferation of SKOV3 cell was not significantly inhibited by TGF-beta1 while it expressed all components of the TGF-beta/Smads signaling pathway. After exposure to TGF-beta1, Smad7 protein in SKOV3 increased transiently and translocated to cytoplasm from nucleus while P-Smad2 translocated into nucleus from cytoplasm. Taken together, the results suggested that the TGF-beta/Smads signaling pathway remained functional in human ovarian cancer cells, HO-8910, HO-8910PM and SKOV3, and the abnormalities of the downstream effectors of Smads proteins might contribute to the resistance of SKOV3 cell to TGF-beta1.
Insights
Transforming growth factor-beta (TGF-beta) resistance in ovarian cancer cells was investigated. Abnormalities in Smad proteins may cause resistance in SKOV3 cells, despite a functional TGF-beta/Smads pathway.
Area of Science:
- Oncology
- Molecular Biology
- Cell Signaling
Context:
- Resistance to transforming growth factor-beta (TGF-beta) is a hallmark of many cancers.
- The TGF-beta/Smads signaling pathway plays a crucial role in cell growth regulation and carcinogenesis.
- Understanding this pathway's function in ovarian cancer is vital for developing targeted therapies.
Purpose:
- To determine the response of ovarian cancer cell lines (HO-8910, HO-8910PM, SKOV3) to TGF-beta1.
- To investigate the roles of TGF-beta/Smads signaling pathway components in ovarian cancer development.
- To elucidate the mechanisms underlying TGF-beta resistance in ovarian cancer cells.
Summary:
- Ovarian cancer cell lines HO-8910, HO-8910PM, and SKOV3 were treated with TGF-beta1 to assess growth inhibition.
- Expression and localization of TGF-beta/Smads pathway components were analyzed using RT-PCR and immunofluorescence.
- SKOV3 cells showed resistance to TGF-beta1's inhibitory effects, with altered Smad7 and P-Smad2 localization, suggesting pathway dysfunction.
Impact:
- The TGF-beta/Smads pathway remains functional in these ovarian cancer cell lines.
- Aberrant regulation of Smads downstream effectors may contribute to TGF-beta resistance in SKOV3 cells.
- Findings provide insights into molecular mechanisms of ovarian cancer progression and potential therapeutic targets.
